Smeele HTW, Röder E, Wintjes HM, et al. - Researchers investigated the feasibility of a modern treatment strategy, including treat-to-target (T2T) and the prescription of tumour necrosis factor (TNF) inhibitors, in cases with rheumatoid arthritis (RA) who wish to conceive or are pregnant. From the Preconception Counseling in Active RA (PreCARA) cohort, they derived patients with a wish to conceive or who are pregnant and treated them according to a modified T2T approach. Comparison of the results of the PreCARA study was done with results of the Pregnancy-induced Amelioration of Rheumatoid Arthritis (PARA) study, a historic reference cohort on RA during pregnancy in which treatment was provided according to the standards of that time (2002–2010). Per outcomes, 75.4% of the patients in the PreCARA cohort were in low disease activity (LDA) or remission before pregnancy increasing to 90.4% in the third trimester, whereas these percentages were 33.2% and 47.3%, respectively, in the PARA cohort. This first study on a modern treatment method in pregnant patients with RA thereby suggest feasibility of attaining LDA and remission during pregnancy, with 90.4% of patients achieving this in the third trimester.